InsiderTrades.com logo
AI breakthrough about to upend industry
From Porter & Company   |   Ad
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
I urge you to watch it now.
Agustin Melian net worth and biography
  • Phone
  • Email
  • Website

Agustin Melian Biography and Net Worth

Insider of AlloVir
Dr. Melian is AlloVir’s Chief Medical Officer & Head of Global Medical Sciences.
Prior to joining AlloVir, Dr. Melian was an SVP in both Global Clinical Development and Medical Sciences at Alexion Pharmaceuticals. During his tenure there, the company achieved record timelines across clinical development including Ultomiris (a >500 patients rare disease development program fully executed from Investigational New Drug (IND) application to filing in

Dr. Melian has a background in DNA transcription and repair. Prior to his industry work, he practiced medicine and conducted Basic Immunology Research at The Brigham and Women’s Hospital in Boston. Dr. Melian graduated cum laude with degrees in Molecular Biophysics and Biochemistry and in Medicine from Yale University.

What is Agustin Melian's net worth?

The estimated net worth of Agustin Melian is at least $201,314.82 as of July 2nd, 2021. Dr. Melian owns 498,304 shares of AlloVir stock worth more than $201,315 as of December 21st. This net worth estimate does not reflect any other assets that Dr. Melian may own. Learn More about Agustin Melian's net worth.

How do I contact Agustin Melian?

The corporate mailing address for Dr. Melian and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on Agustin Melian's contact information.

Has Agustin Melian been buying or selling shares of AlloVir?

Agustin Melian has not been actively trading shares of AlloVir over the course of the past ninety days. Most recently, Agustin Melian sold 18,689 shares of the business's stock in a transaction on Monday, October 4th. The shares were sold at an average price of $23.91, for a transaction totalling $446,853.99. Learn More on Agustin Melian's trading history.

Who are AlloVir's active insiders?

AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.

Are insiders buying or selling shares of AlloVir?

In the last year, insiders at the sold shares 53 times. They sold a total of 211,951 shares worth more than $149,284.16. The most recent insider tranaction occured on November, 19th when CAO Brett R Hagen sold 554 shares worth more than $304.70. Insiders at AlloVir own 32.1% of the company. Learn More about insider trades at AlloVir.

Information on this page was last updated on 11/19/2024.

Agustin Melian Insider Trading History at AlloVir

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/4/2021Sell18,689$23.91$446,853.99View SEC Filing Icon  
9/28/2021Sell3,750$24.12$90,450.00View SEC Filing Icon  
9/15/2021Sell800$24.03$19,224.00View SEC Filing Icon  
7/2/2021Sell18,586$19.99$371,534.14498,304View SEC Filing Icon  
4/5/2021Sell18,212$23.89$435,084.68View SEC Filing Icon  
3/22/2021Sell3,750$25.97$97,387.50516,516View SEC Filing Icon  
See Full Table

Agustin Melian Buying and Selling Activity at AlloVir

This chart shows Agustin Melian's buying and selling at AlloVir by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AlloVir Company Overview

AlloVir logo
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $0.40
Low: $0.40
High: $0.47

50 Day Range

MA: $0.65
Low: $0.40
High: $1.01

2 Week Range

Now: $0.40
Low: $0.40
High: $2.36

Volume

1,052,281 shs

Average Volume

595,584 shs

Market Capitalization

$46.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59
AI breakthrough about to upend industry
From Porter & Company   |   Ad
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
I urge you to watch it now.